MedPath

An integrated optimization of Surgery and radioTherApy techniques to impRove cosmetic outcome and quaLity of life In breast conserviNG therapy for breaSt cancer patient

Not yet recruiting
Conditions
Breast cancer
Registration Number
NL-OMON22078
Lead Sponsor
Erasmus MC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
750
Inclusion Criteria

•Female patients aged = 18 years
•History of BCT with adjuvant radiation therapy for non-metastatic, histologically proven invasive breast cancer (pT1-3N0-2a) or DCIS. In light of BCT adjuvant systemic treatment (i.e. endocrine therapy, chemotherapy and immune therapy) is allowed.
•Breast conserving surgery between 1st of January 2016 and 31th of December 2018
•Treated according to the currently applied dose fractionation schedules, i.e. whole breast radiotherapy, with or without boost
•Adequate understanding of the Dutch language and written informed consent

Exclusion Criteria

•Any breast surgery or re-irradiation on the breast area after BCT
•Progression of disease (and additional treatment) since BCT
•Patients who received partial breast irradiation
• Current pregnancy or breast feeding

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary focus of this project will be to determine which different combinations of (oncoplastic reconstructive) surgery and radiotherapy techniques, in the context of breast conserving therapy for (pre-invasive) breast cancer, contribute the most to the development of fibrosis.
Secondary Outcome Measures
NameTimeMethod
To assess the relation between the presence and severity of fibrosis, cosmetic outcome and different QoL domains and symptoms.
© Copyright 2025. All Rights Reserved by MedPath